Skip to main content
Equibles
RPRX logo

RPRX · Royalty Pharma plc

Track RPRX — free

Use RPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.24 -1.12 (-1.92%) At close · Oct 1
Russell 1000 member Rebalance outlook locked
Market Cap
$33.47B
Shares
575.00M
Volume · Oct 1 3.25M Avg daily vol (3M) 2.92M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$58.36 Open$58.07 Day$57.70–58.64 52W close$35.28–63.96 Avg vol 30d3.0M Short int11.6M · 2.0% float · 3.3d Short vol51% Last earningsAug 5, 2026 DataJun 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 5 wks
Latest filing: 10-Q
filed Aug 5, 2026
Q2 2026 earnings call transcript
call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.54B
Trailing 12 months
Net income (TTM)
$812.00M
Trailing 12 months
Revenue growth YoY
+16.5%
Year over year
Operating margin
59.6%
Trailing 12 months
P / E (TTM)
31.2
Trailing earnings · reciprocal yield 3.2%
FCF yield
—
TTM · current market cap
Return on invested capital
8.4%
Trailing 12 months
Net cash
−$8.15B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.0%
Year over year · fewer shares
Price change (1Y)
+65.4%
Trailing year
Short interest
2.0%
Latest settlement · 3.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very Low
Market backdrop VIX 16.4 · calm Equity put/call 0.57
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +15%
above
Price vs 50-day avg −2%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 80%
mid-range
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +21%
trailing
YTD return +51%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $59 › 200d $51 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +108 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.03% of float · ▼ -2.2% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
651 holders — near 3-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Fair
Revenue growth +5%
Y/Y
EPS growth −7%
Y/Y
Valuation P/E 31.1
below peers
Buyback $1.7B
remaining
Balance sheet $8.3B
net debt
Quant / Vol
risk profile
Very Low
Volatility 23%
annualized · 1-yr
Max drawdown −10%
past year
ATR 2.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 5, 2026
full year 2026
Portfolio receipts Initiated $3.4B – $3.5B
prior FY $2.38B midpoint +45.1% Y/Y
Operating and professional costs as a percentage of portfolio re Initiated 5.5% – 6.5%
Interest paid Initiated $350M – $360M
Milestones and other contractual receipts Initiated $60M
by 2030
Portfolio receipts at least $4.7B
prior FY $2.38B midpoint +97.6% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+15% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
80% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $59 › 200d $51 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +108 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.03% of float · ▼ -2.2% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
651 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $35 Now $58 · 80% Range high $64
vs 200-day avg +15% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RPRX
Royalty Pharma plc
this stock
$33.47B +51.0% +5.1% 31.1 2.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
651
% held
64.0%
Net QoQ
+12.0M sh
Top holder
MORGAN STANLEY
Held Float
View
Held by Funds
Fund positions
192
View
Short & Settlement
Short Interest Falling
Shares short
11.6M
Days to cover
3.3d
Change
-256.2K sh
View
Short Volume
Short vol %
51%
As of
Oct 1, 2026
Short Total
View
Fails to Deliver
FTD shares
19.6K
Value
$1.2M
As of
Sep 3, 2026
View
Off-Exchange
Off-exchange %
41.5%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.4B
Net income (FY)
$770.9M
EPS diluted
$1.78
View
Buybacks
Authorized
$3.0B
Remaining
$1.7B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
13
View
Proposed Sales
Value
$238.8K
Shares
4.1K
Filed
Sep 28, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 23, 2026
View

Performance

5D 20D 120D MTD YTD
RPRX +1.2% -6.4% +20.8% -5.0% +51.0%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +1.9% -6.5% +8.7% -4.4% +39.2%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$3.00B
Spent (derived)
$1.30B
Remaining
$1.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 10 filings 10 filers Visit website Investor relations